Cellipont Bioservices has announced a strategic collaboration with BobcatBio to provide contract manufacturing support for RB-1355, a macrophage-based cell therapy currently in clinical development. Under the agreement, Cellipont will manufacture Phase I cell therapy products to support BobcatBio’s ongoing clinical
Apertura Gene Therapy has entered into a strategic manufacturing collaboration with Viralgen, a contract development and manufacturing organization (CDMO), to support gene therapy programs based on its TfR1 CapX AAV capsid. The collaboration is intended to provide Apertura licensees with
OXB has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian contract development and manufacturing organization (CDMO), to provide access to its proprietary viral vector platforms. The agreement follows a non-binding term sheet signed
ValGenesis has announced the deployment of its e-Logbook solution at LOTTE Biologics, a contract development and manufacturing organization (CDMO) headquartered in Seoul, South Korea. The system has gone live at the company’s satellite quality control laboratory and is intended to
Celltrion has entered into a contract manufacturing agreement with an undisclosed global pharmaceutical company to supply drug substance over a three-year period from 2027 to 2029. The contract is valued at approximately KRW 294.9 billion and may increase to KRW
Axplora has announced a $60 million investment programme at its Farmabios site in Gropello Cairoli, Italy, including the construction of a new 4,500 m², three-storey R&D and laboratory hub. The facility is designed to expand development and analytical capacity for
SK pharmteco has completed a U.S. Food and Drug Administration (FDA) inspection of its small molecule manufacturing facility in La Porte, Texas, with no Form 483 observations issued. The inspection, conducted from 9 to 12 February 2026, concluded with a
ST Pharm has signed an agreement valued at approximately 89.7 billion won ($59.8 million) to supply active pharmaceutical ingredients (APIs) for oligonucleotide therapeutics to a European pharmaceutical company. The client and product name were not disclosed due to confidentiality clauses.
1Q Health Group has acquired EHF Production, a Netherlands-based contract manufacturer specializing in dietary supplements. The acquisition adds 63 employees to the group and expands its presence in the European health and wellness sector. EHF Production has more than 25
Piramal Pharma Solutions has announced the completion of its 1,500th antibody-drug conjugate (ADC) batch at its bioconjugate development and manufacturing facility in Grangemouth, UK. The milestone batch was a commercial oncology ADC, marking continued activity at the site across clinical,
